Linatab E 10 mg+5 mg (Tablet)

Indications

• Adjunct to diet and exercise
• Improves glycemic control
• Type 2 diabetes mellitus

Pharmacology

• Inhibits DPP-4 enzyme
• Increases active incretin hormones
• Stimulates insulin release
• Decreases glucagon levels
• Reduces hepatic glucose output
• Inhibitor of Sodium-glucose co-transporter 2 (SGLT2)

Dosage & Administration

• Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily
• Taken in the morning
• With or without food
• Increased dose to 25 mg Empagliflozin and 5 mg Linagliptin once daily
• Assess renal function before initiating
• Do not initiate if eGFR is below 45 mL/min/1.73 m²
• Discontinue if eGFR falls below 45 ml/min/1.73 m²

Interaction

• Coadministration with diuretics increases urine volume and frequency of voids
• Increased risk of hypoglycemia when coadministered with Insulin or Insulin Secretagogues
• Rifampin decreases Linagliptin exposure
• Inhibitor of P-glycoprotein or CYP3A4 Enzymes
• Increases urinary glucose excretion
• Interference with 1,5-anhydroglucitol (1,5-AG) Assay

Contraindications

• Severe renal impairment
• End-stage renal disease
• Dialysis
• History of hypersensitivity reaction to Linagliptin or Empagliflozin

Side Effects

• Pancreatitis
• Ketoacidosis
• Volume Depletion
• Urosepsis and Pyelonephritis
• Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene)
• Genital Mycotic Infections
• Hypersensitivity Reactions
• Severe and Disabling Arthralgia
• Bullous Pemphigoid
• Heart Failure

Pregnancy & Lactation

• Not recommended during second and third trimesters of pregnancy
• Limited available data in pregnant women
• Risks associated with poorly controlled diabetes in pregnancy

Precautions & Warnings

• Precaution should be taken in disease conditions like Pancreatitis, Hypotension, Ketoacidosis, Acute kidney injury
• Urosepsis and Pyelonephritis
• Hypoglycemia
• Genital Mycotic Infections
• Hypersensitivity
• Acute pancreatitis
• Volume Depletion
• Urinary tract infections
• Necrotizing fasciitis of the perineum (Fournier’s gangrene)
• Heart Failure

Overdose Effects

• Contact Poison Control Center in case of overdose
• Employ usual supportive measures
• Clinical monitoring
• Institute supportive treatment
• Removal by hemodialysis not studied

Therapeutic Class

• Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

• Store below 30° C temperature
• Keep away from light and wet place
• Keep out of reach of children

Related Brands

• Linatab E 25 mg+5 mg (Tablet) - incepta-pharmaceuticals-ltd
• Emazid L 10 mg+5 mg (Tablet) - eskayef-pharmaceuticals-ltd
• Emazid L 25 mg+5 mg (Tablet) - eskayef-pharmaceuticals-ltd
• Limpa 25 mg+5 mg (Tablet) - aristopharma-ltd
• Limpa 10 mg+5 mg (Tablet) - aristopharma-ltd